SCHEMBL3090974

SCHEMBL3090974

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccc(Cl)cc2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
KAT6A Q92794 1/20 0.48
MAPT P10636 4/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PRMT1 Q99873 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA9 Q16790 1/20 0.44
PPARA Q07869 1/20 0.43
HSD17B10 Q99714 1/20 0.43
F10 P00742 1/20 0.43
GPR27 Q9NS67 1/20 0.43
LARS1 Q9P2J5 1/20 0.42
F2 P00734 1/20 0.41
ENPP3 O14638 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102970 0.93 MMP9 (0.46) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3093901 0.93 MMP9 (0.46) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3092998 0.92 NPC1 (0.51) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3090792 0.92 NPC1 (0.51) MEN1KMT2ANPC1RAB9AKAT6A
SCHEMBL3097645 0.92 KAT6A (0.49) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL3088948 0.92 PRMT1 (0.47) MEN1KMT2AMAPTGAAPRMT1
SCHEMBL3093732 0.92 LARS1 (0.44) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL3090637 0.92 RAB9A (0.48) MEN1KMT2ARAB9AMAPTGPR27
SCHEMBL15000247 0.91 LARS1 (0.49) KAT6AF10LARS1F2
SCHEMBL3100199 0.91 NPC1 (0.53) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MEN1 2509/4885KMT2A 1948/4885NPC1 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.